VLN3 Antibody

What is VLN3 and how does it function in comparison to other villin proteins?

VLN3 (VILLIN3) is an actin-binding protein in Arabidopsis that belongs to the villin family. Like its isovariant VLN1, VLN3 demonstrates F-actin bundling capabilities. According to in vitro studies, VLN3 bundles actin filaments in a calcium-independent manner, which is biochemically similar to VLN1's activity .

The protein has a molecular weight of approximately 106-kD and can be expressed as a nonfusion protein in Escherichia coli and purified using ion exchange and affinity chromatography methods. Importantly, both VLN1 and VLN3 function to organize actin filaments into higher-order structures, which is critical for proper cytoskeletal organization in plant cells .

What experimental methods are most effective for assessing VLN3 bundling activity?

Several complementary approaches are recommended for rigorous assessment of VLN3 bundling activity:

• Low-speed cosedimentation assays: This is the primary method used to evaluate bundling capability. Since individual actin filaments do not sediment at 13,500 g, significant actin presence in the pellet indicates bundling activity. Studies have shown that VLN3 causes a dose-dependent increase in pelleted actin, confirming its bundling function .

• Fluorescence microscopy: Direct visualization of VLN3-actin interactions provides spatial information about bundle formation.

• Binding affinity measurements: Experiments revealed an apparent Kd value of 1.1 ± 0.6 μM for VLN3 binding to F-actin, which was not statistically different from measurements obtained using high-speed cosedimentation assays .

A comprehensive assessment should include both biochemical assays and imaging techniques to fully characterize bundling activity.

How should researchers optimize recombinant VLN3 expression and purification?

Based on successful experimental protocols:

• Expression system selection: Use E. coli with a T7 vector system for recombinant VLN3 expression. This system has been demonstrated to yield functional protein at sufficient quantities for biochemical assays .

• Purification strategy: Implement a two-step purification protocol:

  • Initial purification via ion exchange chromatography

  • Secondary purification using affinity chromatography

• Quality control: Verify protein purity (should exceed 80%) via SDS-PAGE and confirm identity using western blotting with antibodies that recognize villin domains (e.g., antibodies against G1-G3 domains of VLN1) .

• Storage considerations: For optimal protein stability, store purified VLN3 in buffer containing reducing agents to prevent disulfide formation, and include glycerol to prevent freeze-thaw damage.

What factors should be considered when designing antibodies for VLN protein recognition?

When developing antibodies for VLN recognition, researchers should consider:

• Epitope selection: Target conserved regions for broad reactivity across villin family members, or unique regions for isoform specificity. The G1-G3 domains appear to contain conserved epitopes that allow cross-reactivity between VLN1 and VLN3 .

• Validation methods: Confirm antibody specificity through multiple approaches:

  • Western blotting against recombinant proteins

  • Immunoprecipitation experiments

  • Immunofluorescence studies on fixed cells/tissues

• Cross-reactivity assessment: Thoroughly test antibodies against related VLN isoforms to ensure specific recognition of the intended target.

How can researchers effectively investigate calcium sensitivity differences between VLN isoforms?

To investigate calcium sensitivity differences:

• Parallel assays: Conduct bundling and severing assays for different VLN isoforms under identical conditions with varying calcium concentrations (0-200 μM range).

• Real-time analysis: Use total internal reflection fluorescence (TIRF) microscopy to directly visualize calcium effects on VLN activity with fluorescently labeled actin.

• Mutational analysis: Create point mutations in putative calcium-binding domains and assess how these alterations affect calcium sensitivity.

• Calcium affinity quantification: Determine binding constants for calcium using isothermal titration calorimetry (ITC) or other biophysical methods.

Research indicates that while some villin family proteins exhibit calcium-dependent activities, VLN3 demonstrates calcium-independent bundling , making comparative studies particularly valuable for understanding regulatory mechanisms.

What approaches can be used to study potential shielding functions of proteins similar to how VlsE protects surface antigens?

Research on VlsE in Borrelia burgdorferi provides a methodological framework for investigating protein shielding functions that can be applied to other systems:

• Differential binding assays: Develop assays comparing antibody binding to target proteins in the presence or absence of potential shielding proteins. For example, immunofluorescence analysis on intact bacteria expressing both a target protein (like Arp) and a potential shielding protein (like VlsE) revealed that VlsE prevented antibody binding to surface antigens .

• Genetic complementation studies: Create constructs expressing the target and/or potential shielding proteins to determine how their co-expression affects antibody recognition and binding. This approach identified that B. burgdorferi expressing both Arp and VlsE were protected from anti-Arp antibodies .

• Passive immunization experiments: Perform in vivo studies using animal models to assess whether protective antibodies lose efficacy when the potential shielding protein is present .

• Flow cytometry analysis: Quantify protein expression levels and antibody binding using flow cytometry and calculate median fluorescence intensity (MFI) to determine changes in antibody accessibility .

What methodologies are recommended for isolating and characterizing broadly neutralizing antibodies against viral targets?

Based on successful HIV-1 antibody research, the following methodologies are recommended:

• Antigen engineering: Design modified antigens that expose conserved, functionally important epitopes. For example, researchers developed antigenically resurfaced glycoproteins specific for the CD4-binding site to isolate broadly neutralizing HIV-1 antibodies .

• B-cell isolation protocol:

  • Use fluorescently labeled antigen probes with flow cytometry

  • Sort single antigen-specific memory B cells (CD19+, CD20+, IgG+)

  • Include modified antigens lacking the target epitope as negative controls

• Antibody gene recovery:

  • Perform single-cell RT-PCR to amplify heavy and light chain variable regions

  • Clone into expression vectors with appropriate constant regions

  • Express as full IgG molecules in mammalian cells

• Comprehensive characterization workflow:

  • Binding specificity (ELISA with wild-type and mutant antigens)

  • Binding kinetics (Surface Plasmon Resonance)

  • Thermodynamic analysis (Isothermal Titration Calorimetry)

  • Functional assays (neutralization assays)

This systematic approach has led to the identification of antibodies like VRC01 and VRC02 that neutralize over 90% of circulating HIV-1 isolates .

How can researchers optimize yeast expression systems for recombinant antibody production?

Based on successful expression of viral proteins for antibody detection:

• Vector design considerations:

  • Select appropriate promoters (GAL1 is commonly used for inducible expression)

  • Include optimal secretion signals for the intended protein

  • Consider codon optimization for Saccharomyces cerevisiae

• Protein engineering strategies:

  • For complex antigens, express truncated versions that maintain key epitopes

  • Create fusion proteins with tags that facilitate purification and detection

  • Evaluate different domain boundaries to maximize expression and solubility

• Expression optimization:

  • Test multiple S. cerevisiae strains

  • Optimize induction conditions (temperature, duration, media composition)

  • Scale up using fed-batch fermentation for larger yields

• Validation approaches:

  • Confirm antigenicity through ELISA with known positive sera

  • Compare performance with commercially available detection systems

  • Test specificity against heterologous antigens/antibodies

This approach has been successfully applied to express nucleoprotein (NP) and truncated neuraminidase subtypes (N3, N7) of avian influenza virus, which were then used to develop specific indirect ELISA systems for antibody detection .

How does the framework region 3 (FWR3) in antibody light chains influence antigen binding and recombinant production?

Recent research has revealed important insights about FWR3 functions:

• Effects on antigen binding:

  • Single residue deletions in VL-FWR3 can be tolerated without significant impact on antigen binding

  • Multiple deletions (e.g., two residues) in VL-FWR3 can additively decrease antigen binding kinetics

  • FWR3 may allosterically influence CDR positioning and flexibility

• Impact on antibody production:

  • Deletions in VL-FWR3 can significantly reduce recombinant antibody secretion levels

  • Effects on secretion appear to be cumulative when multiple residues are affected

• Allosteric effects:

  • Modifications in VL-FWR3 can allosterically affect distant binding sites

  • Research has shown that deletions in FWR3 can impact Protein L binding to FWR1, demonstrating long-range structural effects

• Experimental approaches:

  • Systematic mutagenesis studies (including deletions and substitutions)

  • Surface plasmon resonance to measure binding kinetics

  • Recombinant expression yield quantification

  • Structural analysis via X-ray crystallography or cryo-EM

These findings highlight the importance of considering framework regions, not just CDRs, when engineering antibodies for research or therapeutic applications.

What strategies are most effective for developing broadly neutralizing antibodies against highly diverse viral strains?

Research on HIV-1 broadly neutralizing antibodies (bNAbs) provides valuable insights for targeting diverse viral strains:

• Target identification:

  • Focus on functionally conserved epitopes (e.g., receptor binding sites)

  • Identify glycan-dependent epitopes that may be conserved despite sequence variation

  • Map vulnerable sites through comprehensive epitope analysis

• Immunization strategies:

  • Extended immunization protocols (longer exposure time correlates with broader responses)

  • Use of diverse viral isolates to stimulate broadly reactive responses

  • Low-level antigen stimulation may promote affinity maturation

• Elite neutralizer analysis:

  • Study natural immune responses in individuals who develop exceptional neutralizing breadth

  • Characterize antibody sequence features (e.g., somatic hypermutation patterns)

  • Identify germline precursors of broadly neutralizing antibodies

• Epitope-specific approaches:

  • V3-glycan supersite targeting has shown particular promise (e.g., antibodies similar to PGT128)

  • CD4 binding site targeting (e.g., VRC01-like antibodies)

  • MPER (membrane-proximal external region) targeting

Research from Angola demonstrated that 56% of HIV-1 patients developed cross-neutralizing, broadly neutralizing, or elite neutralizing responses, with most targeting the V3-glycan supersite. This was associated with longer infection time, specific viral subtypes, lower CD4+ T cell counts, higher age, and higher titer of C2V3C3-specific antibodies .